HBV and HIV co-infection: Impact on liver pathobiology and therapeutic approaches

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) co-infection is a significant global health concern.
• Approximately 90% of HIV-infected individuals are HBV seropositive, with 5%-40% experiencing chronic infection.
• Liver-related mortality is over 17 times higher in HIV-HBV co-infected individuals compared to HBV mono-infection.

Purpose of the Study:

• To highlight the severe consequences of HBV-HIV co-infection on liver disease progression.
• To underscore the complexity of HBV-HIV co-infection in altering hepatitis B natural history and complicating management.
• To emphasize the need for further research into the molecular mechanisms underlying HBV-HIV interactions.

Main Methods:

• Review of existing literature on HBV-HIV co-infection and its impact on liver disease.
• Analysis of epidemiological data regarding prevalence and mortality rates.
• Examination of studies on HIV's effect on hepatocyte biology and limited data on HBV-HIV protein interactions.

Main Results:

• HIV co-infection dramatically accelerates liver disease progression, leading to a wide spectrum of liver pathologies.
• HIV significantly alters the course of chronic hepatitis B, complicating treatment strategies.
• There is a substantial knowledge gap regarding the specific molecular interactions between HBV and HIV proteins.

Conclusions:

• HBV-HIV co-infection presents a complex clinical challenge with profound implications for liver health.
• Further investigation into the molecular mechanisms of HBV-HIV interaction is essential for therapeutic advancements.
• Effective management strategies require a deeper understanding of how these viruses interact within the host.